Endocrine Abstracts

Background: Long-term studies evaluating mortality in patients with non-functioning (NF) pituitary tumors (PitNets) are limited, although standardized mortality ratios (SMR) in these patients are reported to be higher than that of general population. There is also no agreement on predictive factors associated to the increased mortality apart from age at diagnosis and glucocorticoid substitution therapy dose.Objective: To assess long-term mortality and as...

Introduction: Current guidelines propose temozolomide (TMZ) as the first-line chemotherapy for aggressive pituitary neuroendocrine tumors (PitNETs), but no clinical trials have been conducted and clinical experience in this context is limited.Patients and methods: A retrospective study of patients with aggressive pitNETs treated with TMZ was conducted by the members of the Neuroendocrinology Working Area of the Spanish Society of Endocrinology and Nutrit...

Objectives: Most transgender persons (0.3-0.5% of total population) are under gender-affirming hormone therapy (GAHT). Several studies have reported an increased morbimortality due to cardiovascular events (CVE), infectious disease and suicide. However, these studies were made on small populations and short follow up. We evaluated the changes on anthropometric variables, risk factors for cardiovascular diseases (CVD) and CVE at 5 and 10 years of follow up in a transgender popu...

Background: The most common tool to test malignancy in the study of thyroid nodules (TN) is ultrasound and fine needle aspiration biopsy (FNAB). However, the sensitivity and specificity of the methods and the effectiveness in thyroid cancer are limited; therefore new methods to study thyroid nodules are required. In this way our goal is to introduce hybrid diffuse optical instruments that are capable to measure and discriminate altered microvascular blood flow, blood volume an...

Introduction: Transsphenoidal surgery (TSS) is the procedure of choice in Cushing disease (CD), with immediate post-operative remission rates ranging between 59 and 94% and recurrence rates between 3 and 46%, both depending upon the definition criteria and the duration of the follow-up. Our aim was to assess the rate of remission, recurrence and persistence of the disease after the first treatment and to identify predictors of remission in the CD population of our center durin...

IntroductionThe pandemic has altered the day-to-day running of hospitals and most of the material and human resources have been made available for COVID-19 care. So have the residents in Endocrinology and Nutrition (MIR), who have been working on the front line, and this has led to alterations in their training programme. In addition, this unexpected and stressful work situation has had psychological consequences. The Spanish Society of Endocrinology and...

Introduction and rationale: Cushing’s syndrome (CS) is a rare disease with hypercortisolism caused either by ACTH excess from a pituitary or non-pituitary tumor or by an ACTH-independent primary adrenal overproduction of cortisol. It is associated with significant comorbidities potentially lethal: hypertension, diabetes, coagulopathy, cardiovascular disease, infections, and osteoporotic fractures. It is usually managed by surgery and/or medical treatment with steroidogene...

Metyrapone treatment in endogenous Cushing’s syndrome. Results from a prospective multicenter, open-label, phase III/IV study: PROMPTBackground: Metyrapone is a steroidogenesis inhibitor approved in Europe for the treatment of endogenous Cushing’s syndrome (CS) based on observational retrospective studies published over more than 50 years. We present data from the first prospective study designed to confirm metyrapone efficacy and good tolera...

BackgroundRetrospective studies led to European approval of the steroidogenesis inhibitor Metyrapone for the treatment of endogenous Cushing’s syndrome (CS). We prospectively showed good efficacy and safety of Metyrapone after 12 weeks (Wk12) treatment in the phase III/IV PROMPT study and now report results of an extension study (EXT) sponsored by HRA Pharma Rare Diseases.DesignThis was a single arm, ope...

In our country, as in others, there is a lack of data on the success rate of transsphenoidal surgery for producing pituitary adenomas. We evaluated the results reported in TESSPAIN, a retrospective multicenter nationwide project that includes all the TSS performed in the participating centers in the period between 2018 and 2022, both included. Surgical treatment success is defined according to the published criteria for each disease: normal IGF-1 and GH after 75 g of oral gluc...